Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma
Hyung Park, Thaddeus Tarpey, Mengling Liu, et al.
JAMA Network Open (2022) Vol. 5, Iss. 1, pp. e2147375-e2147375
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 89
Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19
Andrea B. Troxel, Eva Petkova, Keith Goldfeld, et al.
JAMA Network Open (2022) Vol. 5, Iss. 1, pp. e2147331-e2147331
Open Access | Times Cited: 45
Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
Mayo Clinic Proceedings Innovations Quality & Outcomes (2023) Vol. 7, Iss. 5, pp. 499-513
Open Access | Times Cited: 28
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 25
Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
Juan G. Ripoll, Ellen K. Gorman, Justin E. Juskewitch, et al.
Blood Advances (2022) Vol. 6, Iss. 23, pp. 5951-5955
Open Access | Times Cited: 24
Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation
Hyung Park, Chang Yu, Liise‐anne Pirofski, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Early administration of COVID‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
Artur Belov, Yin Huang, Carlos H. Villa, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 6, pp. 770-779
Open Access | Times Cited: 15
Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study
Manuel Rojas, Yhojan Rodríguez, Juan C. Hernández, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Optimizing the use of ketamine to reduce chronic postsurgical pain in women undergoing mastectomy for oncologic indication: study protocol for the KALPAS multicenter randomized controlled trial
Jing Wang, Lisa Doan, Deborah Axelrod, et al.
Trials (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review
Usha Rani Kandula, Techane Sisay Tuji, Dinkinesh Begna Gudeta, et al.
Journal of Blood Medicine (2023) Vol. Volume 14, pp. 159-187
Open Access | Times Cited: 7
Convalescent plasma and COVID‐19: Time for a second—second look?
Michael J. Joyner, Rickey E. Carter, DeLisa Fairweather, et al.
Transfusion Medicine (2022) Vol. 33, Iss. 1, pp. 16-20
Open Access | Times Cited: 10
Impact of the PATH Statement on Analysis and Reporting of Heterogeneity of Treatment Effect in Clinical Trials: A Scoping Review
Joe V. Selby, Carolien C. H. M. Maas, Bruce Fireman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
A Bayesian multivariate hierarchical model for developing a treatment benefit index using mixed types of outcomes
Danni Wu, Keith Goldfeld, Eva Petkova, et al.
BMC Medical Research Methodology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Developing a Bayesian hierarchical model for a prospective individual patient data meta-analysis with continuous monitoring
Danni Wu, Keith Goldfeld, Eva Petkova
BMC Medical Research Methodology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses
Yi-Chan Lin, David H. Evans, Ninette F. Robbins, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 7
High‐titer post‐vaccine COVID‐19 convalescent plasma for immunocompromised patients during the first omicron surge
Ralph Tayyar, Lisa Wong, Alex Dahlen, et al.
Transplant Infectious Disease (2023) Vol. 25, Iss. 2
Open Access | Times Cited: 3
Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19
Cindy Ke Zhou, Monica Bennett, Carlos H. Villa, et al.
PLoS ONE (2022) Vol. 17, Iss. 8, pp. e0273223-e0273223
Open Access | Times Cited: 5
Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin
Sangmee Bae, Emmanuelle Faure-Kumar, Kathie G. Ferbas, et al.
Rheumatology International (2023) Vol. 43, Iss. 9, pp. 1629-1636
Open Access | Times Cited: 2
Development of a metabolome-based respiratory infection prognostic during COVID-19 arrival
John I. Robinson, Laura R. Marks, Andrew L. Hinton, et al.
mBio (2024)
Closed Access
Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19
Deblina Raychaudhuri, Purbita Bandopadhyay, Ranit D’Rozario, et al.
Mayo Clinic Proceedings Innovations Quality & Outcomes (2022) Vol. 6, Iss. 6, pp. 511-524
Open Access | Times Cited: 3
Coronavirus Disease 2019 Convalescent Plasma Reaches the Slope of Enlightenment in the Gartner Hype Cycle
Shmuel Shoham
Clinical Infectious Diseases (2023) Vol. 76, Iss. 12, pp. 2087-2089
Closed Access | Times Cited: 1
Factors related to the development of high antibody titres against SARS‐CoV‐2 in convalescent plasma donors from the ConPlas‐19 trial
Irene Romera, C. Avendaño, Carolina Villegas Da Ros, et al.
Vox Sanguinis (2023) Vol. 119, Iss. 1, pp. 27-33
Open Access | Times Cited: 1
High-Dose Convalescent Plasma for Treatment of Severe COVID-19
Daniele Focosi, Arturo Casadevall
Emerging infectious diseases (2022) Vol. 28, Iss. 5, pp. 1083-1083
Open Access | Times Cited: 2
Late Treatment for COVID-19 With Convalescent Plasma
Jonathon W. Senefeld, Nigel Paneth, Rickey E. Carter, et al.
CHEST Journal (2022) Vol. 162, Iss. 5, pp. e283-e284
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top